Towards a diagnostic and therapeutic consensus in male osteoporosis
- 21 April 2011
- journal article
- review article
- Published by Springer Nature in Osteoporosis International
- Vol. 22 (11), 2789-2798
- https://doi.org/10.1007/s00198-011-1632-z
Abstract
Summary The consensus views on osteoporosis in men are reported. Introduction A workshop was convened within a meeting on osteoporosis in men to identify areas of consensus amongst the panel (the authors) and the participants of the meeting. Methods A public debate with an expert panel on preselected topics was conducted. Results and Conclusions Consensus views were reached on diagnostic criteria and several aspects on the pathophysiology and treatment of osteoporosis in men.Keywords
This publication has 110 references indexed in Scilit:
- A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnoverJournal of Bone and Mineral Research, 2010
- BMI and fracture risk in older men: The osteoporotic fractures in men study (MrOS)Journal of Bone and Mineral Research, 2010
- Adverse Events Associated with Testosterone AdministrationNew England Journal of Medicine, 2010
- Reproducibility of direct quantitative measures of cortical bone microarchitecture of the distal radius and tibia by HR-pQCTBone, 2010
- Levelling off of prevalence of obesity in the adult population of Sweden between 2000/01 and 2004/05BMC Public Health, 2010
- Bone mineral density variation in men is influenced by sex-specific and non sex-specific quantitative trait lociBone, 2009
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate CancerNew England Journal of Medicine, 2009
- Rate and circumstances of clinical vertebral fractures in older menOsteoporosis International, 2007
- Androgen deprivation therapy for prostate cancer: new concepts and concernsCurrent Opinion in Endocrinology, Diabetes and Obesity, 2007
- Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate CancerJournal of Clinical Oncology, 2007